Biofil Chemicals and Pharmaceuticals Ltd

BIOFILCHEM
Health CarePharmaceuticals
SmallcapWith a market cap of ₹96 cr, stock is ranked 1,979
High RiskStock is 3.66x as volatile as Nifty
59.100.95 (-1.58%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
SmallcapWith a market cap of ₹96 cr, stock is ranked 1,979
High RiskStock is 3.66x as volatile as Nifty

Key Metrics

PE RatioPE Ratio
76.94
PB RatioPB Ratio
5.96
Dividend YieldDiv. Yield
Sector PESector PE
38.10
Sector PBSector PB
5.08
Sector Div YldSctr Div Yld
0.68%

Forecast & RatingsDetailed Forecast 

Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Biofil Chemicals and Pharmaceuticals Limited is engaged in pharmaceuticals and chemicals business. The Company is also engaged in manufacturing plastic products for the purpose of packing of pharmaceutical product and other plastic products.

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

See Plans

Financial TrendFinancial statements 

201820192020202112.4623.2329.8636.550.470.481.201.25
Revenue
Profit
All values in ₹ cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent NewsAll news 

Hmm, looks like data is unavailable here. Please come back after some time
See all news

Recent EventsAll events 

Financial Results Updates 
Announced OnNov 13, 2021

Biofil Chemicals & Pharmaceuticals Limited has informed the Exchange regarding ''.This is in Continuation of our letter dated 12th November, 2021 regarding submission of Un-audited Financial Statements for the Quarter and half year ended on 30th September, 2021.Pursuant to Regulation 33(3)(d) of SEBI(LODR) Regulations, 2015, the Un-audited Financial Statements of the Company for the Quarter and Half Year ended on 30th September, 2021 along with the Statement of Assets and Liabilities, Cash Flow Statement, Segment Reporting and Limited Review Report in the PDF Format has been submitted in the prescribed time. Further, we would like to inform that due to typographically error of wrong entry of profit before tax and failing to enter amount of Adjustments for provisions, current in the Cash Flow Statement, PDF file was wrongly uploaded on stock exchange, however please note that there was no change in Un-audited financial results, Statement of assets & Liabilities and Segment Reporting, therefore we hereby submitting Revised Cash Flow Statement only for half year ended 30th September, 2021 after correction for your reference and records. Further, we would like to inform that Company has submitted the corrected Un-audited financial statement for quarter and half year ended 30th September, 2021 along with cash flow statement in XBRL mode to the exchange. | Download

Biofil Chemicals & Pharmaceuticals Limited has informed the Exchange regarding ''.This is in Continuation of our letter dated 12th November, 2021 regarding submission of Un-audited Financial Statements for the Quarter and half year ended on 30th September, 2021.Pursuant to Regulation 33(3)(d) of SEBI(LODR) Regulations, 2015, the Un-audited Financial Statements of the Company for the Quarter and Half Year ended on 30th September, 2021 along with the Statement of Assets and Liabilities, Cash Flow Statement, Segment Reporting and Limited Review Report in the PDF Format has been submitted in the prescribed time. Further, we would like to inform that due to typographically error of wrong entry of profit before tax and failing to enter amount of Adjustments for provisions, current in the Cash Flow Statement, PDF file was wrongly uploaded on stock exchange, however please note that there was no change in Un-audited financial results, Statement of assets & Liabilities and Segment Reporting, therefore we hereby submitting Revised Cash Flow Statement only for half year ended 30th September, 2021 after correction for your reference and records. Further, we would like to inform that Company has submitted the corrected Un-audited financial statement for quarter and half year ended 30th September, 2021 along with cash flow statement in XBRL mode to the exchange. | Download

Copy of Newspaper Publication 
Announced OnNov 13, 2021

Biofil Chemicals & Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication | Download

Biofil Chemicals & Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication | Download

Financial Result Updates 
Announced OnNov 12, 2021

Biofil Chemicals & Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2021. | Download

Biofil Chemicals & Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2021. | Download

See all events